MX2011009700A - Derivado de amida. - Google Patents

Derivado de amida.

Info

Publication number
MX2011009700A
MX2011009700A MX2011009700A MX2011009700A MX2011009700A MX 2011009700 A MX2011009700 A MX 2011009700A MX 2011009700 A MX2011009700 A MX 2011009700A MX 2011009700 A MX2011009700 A MX 2011009700A MX 2011009700 A MX2011009700 A MX 2011009700A
Authority
MX
Mexico
Prior art keywords
group
integer
compound
substituent group
neurokinin
Prior art date
Application number
MX2011009700A
Other languages
English (en)
Inventor
Takuya Ikeda
Takanori Yamazaki
Hiroshi Tsuchida
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2011009700A publication Critical patent/MX2011009700A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un compuesto o una sal farmacológicamente aceptable del mismo que tiene excelente efecto antagonista sobre un receptor NK1 de neuroquinína, un receptor NK2 de neuroquinina y un receptor M3 de muscarina y es útil como un agente terapéutico para el asma bronquial, enfermedades pulmonares obstructivas crónicas o similares; un compuesto representado por la fórmula general (I): [donde R1 representa un átomo de hidrógeno, un grupo alquilo de C1-C6 o similar; R2 representa un átomo de hidrógeno, un grupo alquilo de C1-C6 o similar; R3 representa un grupo fenilo que puede sustituirse con 1 a 5 grupo(s) independientemente seleccionados del grupo sustituyente A, o similar; R4 representa un grupo fenilo que puede sustituirse con 1 a 5 grupo(s) independientemente seleccionados del grupo sustituyente A o similar; L1 representa un grupo alquileno de C1-C10 o similar; L2 representa un grupo carbonilo, un grupo representado por la fórmula -N(R5)-C(=O)-, un grupo representado por la fórmula -C(=O=-N(R5)- o similar; R5 representa un átomo de hidrógeno, un grupo alquilo de C1-C6 o similar; E representa un grupo fenileno que puede sustituirse con 1 a 4 grupo(s) independientemente seleccionados del grupo sustituyente A, o el similar; m es un entero de 1 a 4; n es un entero de 0 a 4; p es un entero de 0 a 2; q es un entero de 1 a 10, r es 1 ó 2; s es 0 ó 1; y un grupo sustituyente A representa el grupo que consiste en un átomo de halógeno, un grupo alquilo de C1-C6, un grupo alquilo halogenado de C1-C6 o similar] o una sal farmacológicamente aceptable del mismo.(ver formula (I)).
MX2011009700A 2009-03-17 2010-03-15 Derivado de amida. MX2011009700A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009065029 2009-03-17
PCT/JP2010/054291 WO2010106988A1 (ja) 2009-03-17 2010-03-15 アミド誘導体

Publications (1)

Publication Number Publication Date
MX2011009700A true MX2011009700A (es) 2011-12-08

Family

ID=42739647

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009700A MX2011009700A (es) 2009-03-17 2010-03-15 Derivado de amida.

Country Status (17)

Country Link
US (1) US8476253B2 (es)
EP (1) EP2409977A4 (es)
JP (1) JPWO2010106988A1 (es)
KR (1) KR20110136813A (es)
CN (1) CN102439007A (es)
AU (1) AU2010225747A1 (es)
BR (1) BRPI1014125A2 (es)
CA (1) CA2755697A1 (es)
CO (1) CO6450684A2 (es)
IL (1) IL215153A0 (es)
MX (1) MX2011009700A (es)
NZ (1) NZ595723A (es)
RU (1) RU2011141794A (es)
SG (1) SG174389A1 (es)
TW (1) TW201036964A (es)
WO (1) WO2010106988A1 (es)
ZA (1) ZA201106792B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138916A1 (ja) * 2010-05-07 2011-11-10 第一三共株式会社 多環式化合物
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
US9745291B2 (en) * 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
JP2017530940A (ja) 2014-08-04 2017-10-19 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
CN110227164B (zh) 2018-03-06 2021-11-23 江苏吉贝尔药业股份有限公司 含酮羰基的疏水性抗肿瘤药物及其缀合物、含有缀合物的纳米制剂及其制备方法及应用
US20240189315A1 (en) 2022-11-09 2024-06-13 Boehringer Ingelheim International Gmbh Cyclic Pyridine Derivatives as cGAS Inhibitors
WO2024099907A1 (en) 2022-11-09 2024-05-16 Boehringer Ingelheim International Gmbh Cyclic benzimidazole derivatives as cgas inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670048C3 (de) 1966-01-26 1980-09-04 C.H. Boehringer Sohn, 6507 Ingelheim Neue Norscopolaminderivate
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
DE4111243A1 (de) 1991-04-08 1992-10-15 Erbsloeh Julius & August In laengsrichtung allseitig geschlossene, unloesbare, feste profilverbindung
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
CN1154240A (zh) * 1995-11-06 1997-07-16 美国辉瑞有限公司 治疗癌症用的nk-1受体拮抗剂
HUP9901639A3 (en) 1996-01-26 2000-10-30 Nattermann A & Cie Therapeutic anti-asthma agents
DK1057827T3 (da) 1998-01-23 2004-01-26 Sankyo Co Spiropiperidinderivater
KR20010083092A (ko) * 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
ATE259641T1 (de) 1999-07-23 2004-03-15 Banyu Pharma Co Ltd Amidderivate
DZ3477A1 (es) 2000-10-12 2002-04-18
DE60210760T2 (de) 2001-04-23 2006-11-23 F. Hoffmann-La Roche Ag Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie
US20040192728A1 (en) 2003-02-03 2004-09-30 Ellen Codd Quinoline-derived amide modulators of vanilloid VR1 receptor
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
NZ543287A (en) 2003-04-15 2008-08-29 Merck & Co Inc Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
JP4853992B2 (ja) * 2004-02-25 2012-01-11 第一三共株式会社 インダノール誘導体
EP1746095A4 (en) 2004-02-25 2009-10-28 Sankyo Co INDANOL DERIVATIVE
US7250414B2 (en) 2004-03-11 2007-07-31 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
WO2005087736A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2006160639A (ja) 2004-12-06 2006-06-22 Sankyo Co Ltd ニューロキニン受容体拮抗剤と抗コリン剤の併用
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7629336B2 (en) 2005-03-10 2009-12-08 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006138218A1 (en) 2005-06-13 2006-12-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007084530A (ja) * 2005-08-22 2007-04-05 Sankyo Co Ltd インダノール誘導体を含有する医薬組成物
CN101678022A (zh) 2006-12-21 2010-03-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
WO2010007561A1 (en) * 2008-07-15 2010-01-21 Pfizer Limited Novel compounds active as muscarinic receptor antagonists

Also Published As

Publication number Publication date
EP2409977A4 (en) 2012-09-26
CA2755697A1 (en) 2010-09-23
AU2010225747A1 (en) 2011-11-10
TW201036964A (en) 2010-10-16
US20120071467A1 (en) 2012-03-22
BRPI1014125A2 (pt) 2016-04-12
ZA201106792B (en) 2012-06-27
SG174389A1 (en) 2011-10-28
EP2409977A1 (en) 2012-01-25
KR20110136813A (ko) 2011-12-21
CN102439007A (zh) 2012-05-02
US8476253B2 (en) 2013-07-02
NZ595723A (en) 2012-10-26
JPWO2010106988A1 (ja) 2012-09-20
RU2011141794A (ru) 2013-04-27
CO6450684A2 (es) 2012-05-31
IL215153A0 (en) 2011-12-29
WO2010106988A1 (ja) 2010-09-23

Similar Documents

Publication Publication Date Title
MX2011009700A (es) Derivado de amida.
GB0510584D0 (en) Organic compounds
EA201171328A1 (ru) Производное замещенного изохинолина
MY177250A (en) Novel nicotinamide derivative or salt thereof
MX2009008465A (es) Nuevas 2-aminooxazolinas como ligandos de taar1.
PE20071009A1 (es) Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3
RS51137B (sr) Derivat benzimidazola i njegova upotreba kao antagonista receptora aii
TW200833675A (en) Nicotinamide derivatives
UA105185C2 (uk) Піроли
NZ561747A (en) (Pyrrol-2-ylmethyl)-indol-1-yl-acetic acid derivatives with PGD2 antagonist activity
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
RS54708B1 (en) ARYLETINYL DERIVATIVES
JO2613B1 (ar) مركبات عضوية
EP2597088A4 (en) P2X4 Receptor Antagonists
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
MX360667B (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
MX2009012380A (es) Compuestos de heteroarilamida pirimidona.
JO3098B1 (ar) مركبات داي فينيل- بيرازول بيريدين وطريقة تحضيرها واستخدامها كمعدلات المستقبل النووي not
WO2008101935A3 (fr) Nouveaux composés dérivés d'indole et compositions pharmaceutiques les contenant
MX2010008362A (es) Derivados de heteroarilamida diazepinopirimidona sustituidos.
MX2011011281A (es) Compuesto de carbinol que tiene un enlazante heterociclico.
MX2010008360A (es) Derivados de oxazepinopirimidona heteroarilamida sustituidos.
MX2010004498A (es) Derivados de ciclohexenoamida y su uso como antagonistas de trpv1.
RS51190B (sr) Aminoacilni derivati kao prolekovi i lekovi za lečenje tromboembolijskih bolesti

Legal Events

Date Code Title Description
FG Grant or registration